Ticker: MASI

Masimo

Healthcare Healthcare Medical - Instruments & Supplies
Price 179.95
Reco Sell Potential 40 Risk 70 Updated 2026-07-27

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Masimo Corporation specializes in non-invasive monitoring technologies, primarily focusing on innovative medical devices that measure blood oxygen levels and other vital signs. Its core products include pulse oximeters, non-invasive hemoglobin monitors, and advanced monitoring solutions for hospitals and home care. Major business segments encompass hospital and home healthcare markets, with revenue primarily derived from product sales and recurring service contracts.

Investment Profile

The investment profile of Masimo is more aligned with balanced investors, given its focus on stable revenue generation through established products while navigating recent fluctuations in earnings. The absence of dividends and moderate growth potential suggests a cautious approach. Investors may consider a medium to long-term horizon for potential value realization, with liquidity reflecting a moderate level of trading activity.

Fundamental metrics (experimental) Updated: 2026-07-26
EPS (TTM) — earnings per share for the last 12 months, $
1.44
Revenue QoQ — quarter-over-quarter revenue growth
-2.2%
EPS surprise
-22.0%
20d volatility
0.0%
last ex-date
2012-11-23
AI recommendation changes
Date Before After Reason
2026-07-19 Hold Sell Weak fundamentals and uncertain market conditions persist.
2026-07-09 Sell Hold Weak fundamentals and uncertain market conditions present risks.
2026-07-02 Hold Sell Weak fundamentals and high risk limit upside potential.
Analyst forecasts
Date Analyst Action Target Price Then
2026-02-17 Stifel Nicolaus Rating Downgraded — → 180 174.8004
2026-02-17 Piper Sandler Rating Downgraded — → 180 174.78
2025-12-05 Wells Fargo Target Raised 187 → 190 142.26
News Page 1 of 1
Masimo Danaher

Analysts expect Danaher (DHR) to accelerate earnings growth following Masimo acquisition and recovery in bioprocessing demand

Danaher is positioned for a significant earnings recovery as it emerges from a pandemic-induced destocking cycle, bolstered by its recent acquisition of Masimo and a rebound in bioprocessing demand. Investors may find the stock undervalued given its improving fundamentals and growth catalysts.